Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: March 3, 2026, 12:49 pm
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 524494 | NSE: IPCALAB

Ipca Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: March 3, 2026, 12:49 pm

Market Cap 38,385 Cr.
Current Price 1,513
Intrinsic Value₹1,101.23
High / Low 1,595/1,168
Stock P/E36.4
Book Value 293
Dividend Yield0.26 %
ROCE14.7 %
ROE12.8 %
Face Value 1.00
PEG Ratio63.52

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Ipca Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Ipca Laboratories Ltd 38,385 Cr. 1,513 1,595/1,16836.4 2930.26 %14.7 %12.8 % 1.00
Ajanta Pharma Ltd 37,078 Cr. 2,968 3,054/2,02236.6 3450.94 %32.4 %24.9 % 2.00
Glaxosmithkline Pharmaceuticals Ltd 42,904 Cr. 2,533 3,516/2,22042.7 1011.66 %63.2 %46.9 % 10.0
J B Chemicals & Pharmaceuticals Ltd 33,354 Cr. 2,077 2,115/1,30344.2 2430.75 %25.8 %20.1 % 1.00
Gland Pharma Ltd 29,570 Cr. 1,795 2,131/1,20024.9 6101.00 %15.8 %11.6 % 1.00
Industry Average20,512.19 Cr1,093.4253.22201.810.38%16.35%15.16%6.10

All Competitor Stocks of Ipca Laboratories Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 1,5461,5121,5852,0342,0532,0332,0932,3552,2452,2472,3092,5562,392
Expenses 1,3301,3311,2781,6731,7221,7111,7001,9131,7821,8181,8922,0121,859
Operating Profit 216181308361331322393441463429416545533
OPM % 14%12%19%18%16%16%19%19%21%19%18%21%22%
Other Income 313645-191-118212620-17933-3038
Interest 11183144332924231722192018
Depreciation 67706990100989910098100100103108
Profit before tax 16912925222528977290345368128331392446
Tax % 32%37%34%39%23%96%31%29%25%49%29%28%18%
Net Profit 11078164136221119924627664233281364
EPS in Rs 4.253.026.425.727.092.357.589.059.782.679.1911.1412.86

Last Updated: March 4, 2026, 8:46 am

Below is a detailed analysis of the quarterly data for Ipca Laboratories Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

  • For Sales, as of Dec 2025, the value is 2,392.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,556.00 Cr. (Sep 2025) to 2,392.00 Cr., marking a decrease of 164.00 Cr..
  • For Expenses, as of Dec 2025, the value is 1,859.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2,012.00 Cr. (Sep 2025) to 1,859.00 Cr., marking a decrease of 153.00 Cr..
  • For Operating Profit, as of Dec 2025, the value is 533.00 Cr.. The value appears to be declining and may need further review. It has decreased from 545.00 Cr. (Sep 2025) to 533.00 Cr., marking a decrease of 12.00 Cr..
  • For OPM %, as of Dec 2025, the value is 22.00%. The value appears strong and on an upward trend. It has increased from 21.00% (Sep 2025) to 22.00%, marking an increase of 1.00%.
  • For Other Income, as of Dec 2025, the value is 38.00 Cr.. The value appears strong and on an upward trend. It has increased from -30.00 Cr. (Sep 2025) to 38.00 Cr., marking an increase of 68.00 Cr..
  • For Interest, as of Dec 2025, the value is 18.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 20.00 Cr. (Sep 2025) to 18.00 Cr., marking a decrease of 2.00 Cr..
  • For Depreciation, as of Dec 2025, the value is 108.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 103.00 Cr. (Sep 2025) to 108.00 Cr., marking an increase of 5.00 Cr..
  • For Profit before tax, as of Dec 2025, the value is 446.00 Cr.. The value appears strong and on an upward trend. It has increased from 392.00 Cr. (Sep 2025) to 446.00 Cr., marking an increase of 54.00 Cr..
  • For Tax %, as of Dec 2025, the value is 18.00%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Sep 2025) to 18.00%, marking a decrease of 10.00%.
  • For Net Profit, as of Dec 2025, the value is 364.00 Cr.. The value appears strong and on an upward trend. It has increased from 281.00 Cr. (Sep 2025) to 364.00 Cr., marking an increase of 83.00 Cr..
  • For EPS in Rs, as of Dec 2025, the value is 12.86. The value appears strong and on an upward trend. It has increased from 11.14 (Sep 2025) to 12.86, marking an increase of 1.72.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 2:46 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 3,2823,1442,8673,1563,2583,7464,6195,3955,7976,2047,6628,8979,505
Expenses 2,5392,6042,5732,7052,8033,0513,7153,8434,4725,2726,3387,1667,581
Operating Profit 7435412944514556959041,5521,3259321,3241,7311,924
OPM % 23%17%10%14%14%19%20%29%23%15%17%19%20%
Other Income 21322111415665595412317-114-139
Interest 303235272822201211481418877
Depreciation 103180163173178182210209232262357398411
Profit before tax 6313611172622915467391,3891,1367458431,1311,296
Tax % 24%28%18%26%18%19%18%17%20%34%37%30%
Net Profit 479254931952394426041,141890479523785941
EPS in Rs 18.9610.073.697.719.4917.6023.9944.9434.8518.5821.5729.0835.86
Dividend Payout % 13%5%0%6%5%9%10%9%11%22%19%14%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-46.97%-63.39%109.68%22.56%84.94%36.65%88.91%-22.00%-46.18%9.19%50.10%
Change in YoY Net Profit Growth (%)0.00%-16.41%173.06%-87.11%62.37%-48.29%52.26%-110.91%-24.18%55.37%40.91%

Ipca Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:11%
5 Years:14%
3 Years:15%
TTM:11%
Compounded Profit Growth
10 Years:13%
5 Years:7%
3 Years:-1%
TTM:44%
Stock Price CAGR
10 Years:14%
5 Years:6%
3 Years:15%
1 Year:-7%
Return on Equity
10 Years:13%
5 Years:14%
3 Years:10%
Last Year:13%

Last Updated: September 5, 2025, 7:50 am

Balance Sheet

Last Updated: December 4, 2025, 1:27 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 25252525252525252525252525
Reserves 1,9342,1832,2342,4302,6633,0973,6024,6765,4395,8176,3076,9237,402
Borrowings 6039358677166284655012658071,4811,4381,3631,279
Other Liabilities 6486697657887999611,1301,0991,3491,3003,3263,4323,557
Total Liabilities 3,2113,8123,8923,9604,1164,5495,2586,0667,6228,62311,09711,74412,263
Fixed Assets 1,3541,8002,0141,9831,9531,9402,0592,0722,4022,7514,5544,2674,371
CWIP 165267129957366133235306140343622777
Investments 91626136871203105059896268629801,203
Other Assets 1,6831,7291,7231,7462,0032,4222,7563,2543,9245,1055,3395,8755,912
Total Assets 3,2113,8123,8923,9604,1164,5495,2586,0667,6228,62311,09711,74412,263

Below is a detailed analysis of the balance sheet data for Ipca Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
  • For Reserves, as of Sep 2025, the value is 7,402.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,923.00 Cr. (Mar 2025) to 7,402.00 Cr., marking an increase of 479.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 1,279.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,363.00 Cr. (Mar 2025) to 1,279.00 Cr., marking a decrease of 84.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 3,557.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,432.00 Cr. (Mar 2025) to 3,557.00 Cr., marking an increase of 125.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 12,263.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11,744.00 Cr. (Mar 2025) to 12,263.00 Cr., marking an increase of 519.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 4,371.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,267.00 Cr. (Mar 2025) to 4,371.00 Cr., marking an increase of 104.00 Cr..
  • For CWIP, as of Sep 2025, the value is 777.00 Cr.. The value appears strong and on an upward trend. It has increased from 622.00 Cr. (Mar 2025) to 777.00 Cr., marking an increase of 155.00 Cr..
  • For Investments, as of Sep 2025, the value is 1,203.00 Cr.. The value appears strong and on an upward trend. It has increased from 980.00 Cr. (Mar 2025) to 1,203.00 Cr., marking an increase of 223.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 5,912.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,875.00 Cr. (Mar 2025) to 5,912.00 Cr., marking an increase of 37.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 12,263.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,744.00 Cr. (Mar 2025) to 12,263.00 Cr., marking an increase of 519.00 Cr..

Notably, the Reserves (7,402.00 Cr.) exceed the Borrowings (1,279.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 5224687092823415015701,0908568069451,321
Cash from Investing Activity + -369-689-218-149-135-165-509-521-851-725-1,215-870
Cash from Financing Activity + -136251-462-159-130-183-137-306427507-553-283
Net Cash Flow 182929-2675153-76264432588-823169

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow140.00-394.00-573.00-265.00-173.00230.00403.00-264.00-806.00931.000.000.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 504157586766715557588077
Inventory Days 272293289290286316294337337276350336
Days Payable 1109714513013715413514010183110111
Cash Conversion Cycle 213237200218216228229251293251321302
Working Capital Days 8268617480888810310271111101
ROCE %28%14%5%9%10%16%19%31%20%11%13%15%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 46.29%46.29%46.29%46.29%46.30%46.30%46.30%44.72%44.72%44.72%44.72%44.72%
FIIs 10.58%10.05%9.86%10.27%10.51%10.85%10.83%11.06%10.75%10.67%10.42%10.62%
DIIs 33.74%34.86%34.72%34.19%34.05%33.46%33.90%35.36%35.73%35.88%36.45%36.99%
Government 0.32%0.32%0.32%0.32%0.32%0.32%0.32%0.32%0.32%0.32%0.32%0.32%
Public 9.06%8.46%8.80%8.93%8.82%9.07%8.64%8.53%8.45%8.41%8.09%7.33%
No. of Shareholders 1,10,29699,88995,93082,80981,16584,75382,97590,18988,30685,58282,87077,673

Shareholding Pattern Chart

No. of Shareholders

Ipca Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Mid Cap Fund 17,994,512 2.87 2646.6317,920,3692026-02-23 07:11:400.41%
Kotak Midcap Fund 12,005,038 2.99 1765.7N/AN/AN/A
DSP Mid Cap Fund 4,290,936 3.31 631.114,637,7282026-02-23 08:52:00-7.48%
Nippon India Growth Mid Cap Fund 3,100,000 1.09 455.95N/AN/AN/A
Axis Midcap Fund 2,635,419 1.25 387.621,810,2342026-02-23 08:52:0045.58%
Kotak Large & Midcap Fund 2,510,000 1.23 369.17N/AN/AN/A
HDFC Balanced Advantage Fund 2,497,123 0.34 367.28N/AN/AN/A
DSP Small Cap Fund 2,101,047 1.92 309.022,320,0002026-02-23 08:52:00-9.44%
DSP Large & Mid Cap Fund 1,949,082 1.64 286.671,950,1962026-02-23 08:52:00-0.06%
DSP ELSS Tax Saver Fund 1,856,293 1.59 273.021,857,3992026-02-23 08:52:00-0.06%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.002.00
Basic EPS (Rs.) 35.1425.8218.5834.8545.01
Diluted EPS (Rs.) 29.0821.5718.5834.8545.01
Cash EPS (Rs.) 46.7234.9429.7045.07107.06
Book Value[Excl.RevalReserv]/Share (Rs.) 273.88304.57233.16219.51371.79
Book Value[Incl.RevalReserv]/Share (Rs.) 273.88304.57233.16219.51371.79
Revenue From Operations / Share (Rs.) 352.37303.71246.13229.79427.28
PBDIT / Share (Rs.) 71.7056.9941.4854.23126.70
PBIT / Share (Rs.) 56.0242.9131.1745.07110.21
PBT / Share (Rs.) 44.5933.2229.3844.77109.50
Net Profit / Share (Rs.) 31.0420.8619.3935.9190.57
NP After MI And SOA / Share (Rs.) 29.0821.5718.5834.8589.87
PBDIT Margin (%) 20.3418.7616.8523.5929.65
PBIT Margin (%) 15.8914.1212.6619.6125.79
PBT Margin (%) 12.6510.9311.9319.4825.62
Net Profit Margin (%) 8.806.867.8715.6221.19
NP After MI And SOA Margin (%) 8.257.107.5415.1621.03
Return on Networth / Equity (%) 10.618.648.0616.0924.24
Return on Capital Employeed (%) 15.1512.4411.5918.5228.48
Return On Assets (%) 6.274.935.4611.5718.78
Long Term Debt / Equity (X) 0.070.090.110.070.00
Total Debt / Equity (X) 0.180.210.240.140.05
Asset Turnover Ratio (%) 0.780.780.760.790.91
Current Ratio (X) 2.632.352.873.042.96
Quick Ratio (X) 1.551.301.911.771.59
Inventory Turnover Ratio (X) 3.551.050.940.951.10
Dividend Payout Ratio (NP) (%) 13.759.2721.5311.478.90
Dividend Payout Ratio (CP) (%) 8.935.6013.849.087.52
Earning Retention Ratio (%) 86.2590.7378.4788.5391.10
Cash Earning Retention Ratio (%) 91.0794.4086.1690.9292.48
Interest Coverage Ratio (X) 21.4210.4623.11178.91177.79
Interest Coverage Ratio (Post Tax) (X) 12.695.6111.80119.46128.08
Enterprise Value (Cr.) 40485.2733899.8720234.9027148.8824038.82
EV / Net Operating Revenue (X) 4.534.403.244.664.44
EV / EBITDA (X) 22.2623.4519.2319.7314.96
MarketCap / Net Operating Revenue (X) 4.264.083.294.624.45
Retention Ratios (%) 86.2490.7278.4688.5291.09
Price / BV (X) 5.484.963.524.905.13
Price / Net Operating Revenue (X) 4.264.083.294.624.45
EarningsYield 0.010.010.020.030.04

After reviewing the key financial ratios for Ipca Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 35.14. This value is within the healthy range. It has increased from 25.82 (Mar 24) to 35.14, marking an increase of 9.32.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 29.08. This value is within the healthy range. It has increased from 21.57 (Mar 24) to 29.08, marking an increase of 7.51.
  • For Cash EPS (Rs.), as of Mar 25, the value is 46.72. This value is within the healthy range. It has increased from 34.94 (Mar 24) to 46.72, marking an increase of 11.78.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 273.88. It has decreased from 304.57 (Mar 24) to 273.88, marking a decrease of 30.69.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 273.88. It has decreased from 304.57 (Mar 24) to 273.88, marking a decrease of 30.69.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 352.37. It has increased from 303.71 (Mar 24) to 352.37, marking an increase of 48.66.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 71.70. This value is within the healthy range. It has increased from 56.99 (Mar 24) to 71.70, marking an increase of 14.71.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 56.02. This value is within the healthy range. It has increased from 42.91 (Mar 24) to 56.02, marking an increase of 13.11.
  • For PBT / Share (Rs.), as of Mar 25, the value is 44.59. This value is within the healthy range. It has increased from 33.22 (Mar 24) to 44.59, marking an increase of 11.37.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 31.04. This value is within the healthy range. It has increased from 20.86 (Mar 24) to 31.04, marking an increase of 10.18.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 29.08. This value is within the healthy range. It has increased from 21.57 (Mar 24) to 29.08, marking an increase of 7.51.
  • For PBDIT Margin (%), as of Mar 25, the value is 20.34. This value is within the healthy range. It has increased from 18.76 (Mar 24) to 20.34, marking an increase of 1.58.
  • For PBIT Margin (%), as of Mar 25, the value is 15.89. This value is within the healthy range. It has increased from 14.12 (Mar 24) to 15.89, marking an increase of 1.77.
  • For PBT Margin (%), as of Mar 25, the value is 12.65. This value is within the healthy range. It has increased from 10.93 (Mar 24) to 12.65, marking an increase of 1.72.
  • For Net Profit Margin (%), as of Mar 25, the value is 8.80. This value is within the healthy range. It has increased from 6.86 (Mar 24) to 8.80, marking an increase of 1.94.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.25. This value is within the healthy range. It has increased from 7.10 (Mar 24) to 8.25, marking an increase of 1.15.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 10.61. This value is below the healthy minimum of 15. It has increased from 8.64 (Mar 24) to 10.61, marking an increase of 1.97.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 15.15. This value is within the healthy range. It has increased from 12.44 (Mar 24) to 15.15, marking an increase of 2.71.
  • For Return On Assets (%), as of Mar 25, the value is 6.27. This value is within the healthy range. It has increased from 4.93 (Mar 24) to 6.27, marking an increase of 1.34.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.07, marking a decrease of 0.02.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.18. This value is within the healthy range. It has decreased from 0.21 (Mar 24) to 0.18, marking a decrease of 0.03.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.78. There is no change compared to the previous period (Mar 24) which recorded 0.78.
  • For Current Ratio (X), as of Mar 25, the value is 2.63. This value is within the healthy range. It has increased from 2.35 (Mar 24) to 2.63, marking an increase of 0.28.
  • For Quick Ratio (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.55, marking an increase of 0.25.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.55. This value is below the healthy minimum of 4. It has increased from 1.05 (Mar 24) to 3.55, marking an increase of 2.50.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 13.75. This value is below the healthy minimum of 20. It has increased from 9.27 (Mar 24) to 13.75, marking an increase of 4.48.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.93. This value is below the healthy minimum of 20. It has increased from 5.60 (Mar 24) to 8.93, marking an increase of 3.33.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 86.25. This value exceeds the healthy maximum of 70. It has decreased from 90.73 (Mar 24) to 86.25, marking a decrease of 4.48.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.07. This value exceeds the healthy maximum of 70. It has decreased from 94.40 (Mar 24) to 91.07, marking a decrease of 3.33.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 21.42. This value is within the healthy range. It has increased from 10.46 (Mar 24) to 21.42, marking an increase of 10.96.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.69. This value is within the healthy range. It has increased from 5.61 (Mar 24) to 12.69, marking an increase of 7.08.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 40,485.27. It has increased from 33,899.87 (Mar 24) to 40,485.27, marking an increase of 6,585.40.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.53. This value exceeds the healthy maximum of 3. It has increased from 4.40 (Mar 24) to 4.53, marking an increase of 0.13.
  • For EV / EBITDA (X), as of Mar 25, the value is 22.26. This value exceeds the healthy maximum of 15. It has decreased from 23.45 (Mar 24) to 22.26, marking a decrease of 1.19.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 24) to 4.26, marking an increase of 0.18.
  • For Retention Ratios (%), as of Mar 25, the value is 86.24. This value exceeds the healthy maximum of 70. It has decreased from 90.72 (Mar 24) to 86.24, marking a decrease of 4.48.
  • For Price / BV (X), as of Mar 25, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.96 (Mar 24) to 5.48, marking an increase of 0.52.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 24) to 4.26, marking an increase of 0.18.
  • For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Ipca Laboratories Ltd as of March 5, 2026 is: ₹1,094.96

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 5, 2026, Ipca Laboratories Ltd is Overvalued by 27.63% compared to the current share price ₹1,513.00

Intrinsic Value of Ipca Laboratories Ltd as of March 5, 2026 is: ₹1,101.23

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 5, 2026, Ipca Laboratories Ltd is Overvalued by 27.22% compared to the current share price ₹1,513.00

Last 5 Year EPS CAGR: 0.57%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 15.92%, which is a positive sign.
  2. The company has higher reserves (4,208.23 cr) compared to borrowings (872.92 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (4.69 cr) and profit (349.15 cr) over the years.
  1. The stock has a high average Working Capital Days of 85.75, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 246.58, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ipca Laboratories Ltd:
    1. Net Profit Margin: 8.8%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 15.15% (Industry Average ROCE: 16.35%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 10.61% (Industry Average ROE: 15.16%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 12.69
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.55
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 36.4 (Industry average Stock P/E: 53.22)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.18
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Ipca Laboratories Ltd. is a Public Limited Listed company incorporated on 19/10/1949 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1949PLC007837 and registration number is 007837. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 6677.92 Cr. and Equity Capital is Rs. 25.37 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals48, Kandivli Industrial Estate, Kandivli (West), Mumbai Maharashtra 400067Contact not found
Management
NamePosition Held
Mr. Premchand GodhaExecutive Chairman
Mr. Ajit Kumar JainManaging Director & CFO
Mr. Pranay GodhaManaging Director & CEO
Mr. Prashant GodhaExecutive Director
Dr.(Ms.) Swati PatankarIndependent Director
Dr. Narendra MairpadyIndependent Director
Mr. Vivek ShiralkarIndependent Director
Mr. Kamal Kishore SethIndependent Director

FAQ

What is the intrinsic value of Ipca Laboratories Ltd?

Ipca Laboratories Ltd's intrinsic value (as of 05 March 2026) is ₹1101.23 which is 27.22% lower the current market price of ₹1,513.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹38,385 Cr. market cap, FY2025-2026 high/low of ₹1,595/1,168, reserves of ₹7,402 Cr, and liabilities of ₹12,263 Cr.

What is the Market Cap of Ipca Laboratories Ltd?

The Market Cap of Ipca Laboratories Ltd is 38,385 Cr..

What is the current Stock Price of Ipca Laboratories Ltd as on 05 March 2026?

The current stock price of Ipca Laboratories Ltd as on 05 March 2026 is ₹1,513.

What is the High / Low of Ipca Laboratories Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Ipca Laboratories Ltd stocks is ₹1,595/1,168.

What is the Stock P/E of Ipca Laboratories Ltd?

The Stock P/E of Ipca Laboratories Ltd is 36.4.

What is the Book Value of Ipca Laboratories Ltd?

The Book Value of Ipca Laboratories Ltd is 293.

What is the Dividend Yield of Ipca Laboratories Ltd?

The Dividend Yield of Ipca Laboratories Ltd is 0.26 %.

What is the ROCE of Ipca Laboratories Ltd?

The ROCE of Ipca Laboratories Ltd is 14.7 %.

What is the ROE of Ipca Laboratories Ltd?

The ROE of Ipca Laboratories Ltd is 12.8 %.

What is the Face Value of Ipca Laboratories Ltd?

The Face Value of Ipca Laboratories Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Ipca Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports